CAMBRIDGE, Mass. and STOCKHOLM, Sweden, Oct. 16, 2014/ PRNewswire/– Moderna Therapeutics today announced a strategic, lasting collaboration with Karolinska Institutet (KI) and Karolinska University Medical facility (KUH) for the discovery and formulation of innovative drugs utilizingsubstance abuse Modernas messenger RNA (mRNA) Therapeutics â¢ technology. mRNA Therapeutics â¢ make it possible for the in vivo production of both intracellular proteins and secreted proteins. As an outcome, Modernas platform has the potential to speed the formulation and manufacture of treatments for numerous conditions that are presently untreatable with existing pharmaceutical techniques.
This job is an essential step in advancing clinical science, said Teacher Hans-Gustaf Ljunggren, Dean of Research at Karolinska Institutet. It will assist attain our usual goal of rapidly advancing brand-new medicine prospects into the center.
Under the terms of the collaboration, Moderna will certainly sponsor research grants for scientists at both organizations to carry out preclinical study with novel mRNA Therapeutics â¢. As this pre-clinical work is successfully finished, Moderna will certainly conduct professional trials of brand-new drug prospects at Karolinska University Hospital.
As a prominent medical center, we continually make every effort to enhance the treatment of major illness, stated Teacher Mats Eriksson, Karolinska University Medical facility. Our clinical analysts are excited to work with Modernas groundbreaking mRNA Therapeutics platform and speed the advancement of new treatments to patients.
To strengthen the scientific and scientific collaboration in between the organizations, and to enhance the output of this vital partnership, Moderna is producing a brand-new lab in Stockholm, Sweden, positioned in the Novum structure next to the Karolinska University Medical facility Huddinge campus.
Moderna is investing greatly to bring mRNA Therapeutics to clients, and our science is speeding up rapidly, stated St phane Bancel, Head of state and founding CEO of Moderna. This partnership puts our mRNA Therapeutics platform in the hands of Karolinskas world-class researchers and professional analysts to develop brand-new drugs and therapeutic techniques that can not be done with little molecules or biologics– bringing brand-new hope to patients with severe diseases.
Strategically, we see this, our very first academic collaboration, as highly complementary to our existing drug discovery and formulation efforts, both with our pharmaceutical partners AstraZeneca and Alexion and with Moderna ventures such as Onkaido, included Bancel. Given the broad potential of this revolutionary drug technology, it was vital to us to work carefully with a leading scholastic clinical institution. We are recognized to be partnering with one of the finestthe very best academic medical research organizations in the world.
For even more informationTo learn more on Karolinska Institutet and Karolinska University Health center, please see ki.se and karolinska.se. For more infoTo find out more on Moderna Therapeutics kindly see modernatx.com.
About Karolinska Institutet
Karolinska Institutet is among the worlds leading clinical universities. Its objective is to add to the improvement of human health through study and education. Karolinska Institutet accounts for over 40 per cent of the clinical scholastic research conducted in Sweden and offers the countrys broadest range of education in medicine and health sciences. Given that 1901 the Nobel Assembly at Karolinska Institutet has actually picked the Nobel laureates in Physiology or Medicine.
About Karolinska University Healthcare facility
Karolinska University Healthcare facility is one of Europes biggest university hospitals and together with Karolinska Institutet has a leading duty within the field of medical breakthroughs. The hospital aims to constantly put the client first by providing the finest possible medical know-how, treatment and care. With innovation and active collaboration with industry and academic community, it is dedicated to being internationally prominent in medicine, research and education.
About Moderna Therapeutics
Moderna is pioneering messenger RNA Therapeutics â¢, a totally brand-new in vivo drug technology that produces human proteins or antibodies inside client cells, which are in turn secreted or active intracellularly. This development platform addresses presently undruggable targets and offers an exceptional alternative to existing drug methods for a broad rangea large range of condition conditions. Moderna has established a broad intellectual homecopyright estate, consisting of more than 320 patent applications covering novel nucleotide chemistries and drug compositions. The business prepares to establish and commercialize its innovative mRNA medicines with a mix of strategic relationships along with brand-new formed ventures, like Onkaido LLC, its oncology Drug Development Business. Started by Flagship VentureLabs, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca and Alexion Pharmaceuticals. www.modernatx.com.
SOURCE Moderna Therapeutics